
This fund aims to closely track the investment returns – both capital appreciation and income – of its underlying index, prior to the deduction of management fees and other operating costs. To achieve this, it typically commits a minimum of 80% of its total assets to the securities that constitute this benchmark. The index itself consists of a collection of companies that have recently gone public through an Initial Public Offering (IPO) and are traded on a U.S. stock exchange. It is classified as a non-diversified fund.
Is IPO's expense ratio expensive, average, or a steal for its category?
Pro reveals the verdict on a 5-tier spectrum calibrated against ICI 2025 industry averages, with strategy-aware bands so the comparison is meaningful.

Aardvark Therapeutics (AARD) Investors: Securities Fraud Class Action Filed, Contact Hagens Berman Before October 13, 2026 Lead Plaintiff Deadli

Anthropic is heading toward a potential blockbuster IPO, fueled by rapid revenue growth, major AI deals and ambitious valuation targets.

Aardvark Therapeutics, Inc. (AARD) Investors with Substantial Losses Have Opportunity to Lead Aardvark Class Action Lawsuit Before October 13 De

Aardvark Therapeutics (AARD) Investors: Securities Fraud Class Action Filed, Contact Hagens Berman Before October 13, 2026 Lead Plaintiff Deadli

The 2026 IPO window blew open this summer. SpaceX's June listing pulled in a reported $86 billion according to Benzinga and other outlets, and Anthropic is now being floated as the next challenger to that record, with OpenAI chatter never far behind.